



Markets
/
Stocks
/
nasdaq-nvs
/

Novartis AG

NVS

View Detailed Chart

105.850USD

-6.400-5.70%

Close 04/04, 16:00（ET）Quotes delayed by 15 min

209.06BMarket Cap

17.51P/E TTM



Novartis AG

105.850

-6.400-5.70%

Company

Intraday

30m

Today

-5.70%

5 Days

-5.96%

1 Month

-6.21%

6 Months

-7.10%

Year to Date

+8.77%

1 Year

+10.50%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 9 analysts

HOLD

Current Rating

110.607

Target Price

4.49%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

150

Total

Median

Average

Company name

Ratings

Analysts

Novartis AG

NVS

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Gilead Sciences Inc

GILD

BioMarin Pharmaceutical Inc

BMRN

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(8)

Neutral(2)

Buy(1)

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.163

Neutral

RSI(14)

39.446

Neutral

STOCH(KDJ)(9,3,3)

28.153

Sell

ATR(14)

2.221

High Vlolatility

CCI(14)

-253.168

Oversold

Williams %R

97.047

Oversold

TRIX(12,20)

0.048

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

109.999

Sell

MA10

110.560

Sell

MA20

111.029

Sell

MA50

108.886

Sell

MA100

104.784

Buy

MA200

108.816

Sell

News

NFL signs Novartis as first pharmaceutical partner-source

NEW YORK, March 13 (Reuters) - The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis NOVN.S, a league source told Reuters on Thursday.

ReutersThu, Mar 13

US appeals court lifts pause on generic version of Novartis' Entresto

WASHINGTON, Jan 16 - Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' NOVN.S blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary pause on MSN's launch.

ReutersThu, Jan 16

Company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Company codeNVS

CompanyNovartis AG

CEODr. Vasant (Vas) Narasimhan, M.D.

Websitehttps://www.novartis.com/